Aditxt's (Nasdaq: ADTX) Adimune(TM) Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI(TM)-100 in Preparation for Planned Psoriasis First-in-Human Trials

Stock Information for Aditxt Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aditxt Inc.

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap(TM) and NeuroEEG(TM) for Telehealth and Tele-neurology Applications
Aditxt, Inc.'s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.'s Proprietary Mitomic(TM) Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
Aditxt, Inc. Regains Compliance with Nasdaq Stockholders' Equity Requirement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.